News Website

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as Fir - GuruFocus

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as Fir GuruFocus

Published: June 9, 2025, 7:13 p.m.

Read Full Article

AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News - GuruFocus

AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News GuruFocus

Published: June 9, 2025, 12:46 p.m.

Read Full Article

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace

Published: June 9, 2025, 12:43 p.m.

Read Full Article

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News GuruFocus

Published: June 9, 2025, 12:18 p.m.

Read Full Article

Phase 3 Trial Launches ENHERTU as First-Line Endometrial Cancer Treatment | CGEN Stock News - Stock Titan

Phase 3 Trial Launches ENHERTU as First-Line Endometrial Cancer Treatment | CGEN Stock News Stock Titan

Published: June 9, 2025, noon

Read Full Article

From Endometriosis to Asherman’s: Ob/Gyn Chair Tackles the Toughest Cases - Yale Medicine

From Endometriosis to Asherman’s: Ob/Gyn Chair Tackles the Toughest Cases Yale Medicine

Published: June 6, 2025, 5:05 p.m.

Read Full Article

Study Links Early-Stage Endometriosis to Fourfold Increase in Sarcopenia Risk - Medical Dialogues

Study Links Early-Stage Endometriosis to Fourfold Increase in Sarcopenia Risk Medical Dialogues

Published: June 6, 2025, 3:30 p.m.

Read Full Article

Alex Marquardt’s CNN Exit Follows Fallout From Defamation Case - MSN

Alex Marquardt’s CNN Exit Follows Fallout From Defamation Case MSN

Published: June 5, 2025, 11:36 p.m.

Read Full Article

Heart diseases to crampy periods: Doctor explains 6 health warnings that women ignore - MSN

Heart diseases to crampy periods: Doctor explains 6 health warnings that women ignore MSN

Published: June 5, 2025, 4:49 p.m.

Read Full Article

Common Gynecological Disorders May Raise Heart Disease Risk in Women, Studies Show - ETV Bharat

Common Gynecological Disorders May Raise Heart Disease Risk in Women, Studies Show ETV Bharat

Published: June 5, 2025, 11:25 a.m.

Read Full Article

Latest Articles

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as Fir - GuruFocus

AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News - GuruFocus

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

Phase 3 Trial Launches ENHERTU as First-Line Endometrial Cancer Treatment | CGEN Stock News - Stock Titan

From Endometriosis to Asherman’s: Ob/Gyn Chair Tackles the Toughest Cases - Yale Medicine

Study Links Early-Stage Endometriosis to Fourfold Increase in Sarcopenia Risk - Medical Dialogues

Alex Marquardt’s CNN Exit Follows Fallout From Defamation Case - MSN

Heart diseases to crampy periods: Doctor explains 6 health warnings that women ignore - MSN

Common Gynecological Disorders May Raise Heart Disease Risk in Women, Studies Show - ETV Bharat

Subscribe to Our Newsletter